These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 3043683)

  • 41. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA; Gilhus NE
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa.
    Ifedi BO; Best CM; Reichel LM
    J Hand Surg Am; 2013 Jun; 38(6):1259-61. PubMed ID: 23707023
    [No Abstract]   [Full Text] [Related]  

  • 45. Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
    Coon EA; Laughlin RS
    J Headache Pain; 2012 Apr; 13(3):255-7. PubMed ID: 22322657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Off-period screaming accompanying motor fluctuations in Parkinson's disease.
    Steiger MJ; Quinn NP; Toone B; Marsden CD
    Mov Disord; 1991; 6(1):89-90. PubMed ID: 2005932
    [No Abstract]   [Full Text] [Related]  

  • 48. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors.
    Artusi CA; Balestrino R; Imbalzano G; Bortolani S; Montanaro E; Tuttobene S; Fabbri M; Zibetti M; Lopiano L
    Parkinsonism Relat Disord; 2020 Jul; 76():98-103. PubMed ID: 31610986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Association between amytrophic lateral sclerosis and Parkinson's disease].
    Alonso-Navarro H; Ruiz-Ezquerro JJ; Adeva-Bartolomé T; Jiménez-Jiménez FJ
    Med Clin (Barc); 2007 Oct; 129(12):478-9. PubMed ID: 17953916
    [No Abstract]   [Full Text] [Related]  

  • 54. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Selection of the optimal device-aided therapy in Parkinson's disease].
    Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
    Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A
    Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
    [No Abstract]   [Full Text] [Related]  

  • 57. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 58. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 60. Dose-dependent memory impairment in Parkinson's disease.
    Huber SJ; Shulman HG; Paulson GW; Shuttleworth EC
    Neurology; 1989 Mar; 39(3):438-40. PubMed ID: 2927659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.